

Feb. 27, 2020

Trans Chromosomics, Inc.

Development of therapeutic monoclonal antibody drug against a new type of coronavirus (COVID-19) using fully human antibody-producing animals

The outbreak of COVID-19 originated in Wuhan, China is not only pressing uncertainty for global economy but also spreading people's fears, anxiety worldwide.

Our company already has cutting edge technologies to challenge COVID-19, i) leading technologies to capture druggable monoclonal antibodies, ii) proprietary fully human monoclonal antibody producing animals.

The priority of our company mission is to “contribute to the health and wellness of the people”.

Therefore, the company board decided to identify therapeutic monoclonal antibodies against COVID-19 as quickly as possible.

We will inform you of the research development initiatives and details as we progress.

★ Development of therapeutic antibody drugs: humanized monoclonal antibodies

There are number of companies devoting efforts to discover therapeutic agents against COVID-19, such as 1) repurposing of existing drugs, 2) discovery of vaccine, 3) monoclonal antibody. Among the various antibody capturing technologies we currently have, we selected DNA immunization method to obtain monoclonal antibodies at the fastest rate. Our focus will be the spike-proteins (S-Protein) expressed on the envelop of COVID-19 which is an essential piece for the virus to enter the body. By using fully human monoclonal antibody producing animals, we expect to provide safer and effective therapeutic antibodies to prevent COVID-19 becoming pandemic.